Evaluating the benefits and adverse effects of an enthracycline-taxane-capecitabine combined regimen in patients with early breast cancer
Metrics: PDF 894 views | HTML 3074 views | ?
Jiantang Zhang1,*, Fangmeng Fu1,*, Yuxiang Lin1,*, Yazhen Chen1, Minjun Lu1, Minyan Chen1, Peidong Yang1, Meng Huang2 and Chuan Wang1
1Department of Breast Surgery, Affiliated Union Hospital of Fujian Medical University, Fuzhou, China
2Fujian Center for Disease Control and Prevention, China
*These authors contributed equally to this work
Chuan Wang, email: firstname.lastname@example.org
Keywords: capecitabine, early breast cancer, disease-free survival, overall survival, side-effects
Received: February 27, 2017 Accepted: July 26, 2017 Published: August 22, 2017
Capecitabine in addition to anthracycline-taxane based regimens for patients with early breast cancer (EBC) has been reported in previous clinical trials, but the reported efficacy of this regimen remained inconsistent. In order to clarify the survival benefit of this regimen, a meta-analysis was performed. The systematic literature search was conducted in PubMed, the Cochrane library and Google scholar. The hazard ratios (HRs) were used to evaluate the efficacy and adverse events. The result indicated that capecitabine combine with an anthracycline-taxane based regimen would significantly improve DFS (HR = 0.87, 95% CI 0.77–0.97) and OS (HR = 0.78, 95% CI 0.66–0.91) compared with the controls. In subgroup analysis, we found that capecitabine improved the DFS in hormone receptor negative (HR = 0.72, 95% CI 0.53–0.92) and triple negative (HR = 0.67, 95% CI 0.49–0.86) EBC patients. However, adding capecitabine might also increase the occurrence of some side-effects, such as hand-foot syndrome, stomatitis and diarrhea. Capecitabine combined with an anthracycline-taxane based regimen maybe effective and well-tolerated by patients with EBC, especially for triple negative breast cancer, and might be a good clinical choice.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.